BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/5/2026 2:51:06 AM | Browse: 3 | Download: 1
 |
Received |
|
2026-05-18 08:27 |
|
Peer-Review Started |
|
2026-05-18 08:27 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-06-16 07:35 |
|
Revised |
|
2026-06-29 16:55 |
|
Publication Fee Transferred |
|
2026-07-07 02:52 |
|
Second Decision by Editor |
|
2026-07-16 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-16 06:20 |
|
Articles in Press |
|
2026-07-16 06:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-20 04:00 |
|
Publish the Manuscript Online |
|
2026-11-05 02:51 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fei Ma, Li-Yun Zheng, Dan-Jun Song, Zhong-Wei Zhao, Fei Cao, Wei-Yuan Hao, Jun-Qi Qiu, Dong Lu and Jia-Ping Zheng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jia-Ping Zheng, MD, PhD, Professor, Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Banshan East Road, Hangzhou 310022, Zhejiang Province, China. zhengjp@zjcc.org.cn |
| Key Words |
Unresectable hepatocellular carcinoma; Regorafenib; Programmed cell death-1 inhibitor; Second-line treatment; Prognostic factors |
| Core Tip |
This multicenter retrospective study provides real-world evidence supporting regorafenib plus programmed cell death-1 (PD-1) inhibitors as second-line therapy for unresectable hepatocellular carcinoma after first-line treatment failure. Combination therapy improved disease control and prolonged progression-free and overall survival. Notably, survival benefit was mainly observed in patients with prior immune checkpoint inhibitor exposure, whereas first-line targeted therapy (lenvatinib or sorafenib) did not influence second-line outcomes. Second-line PD-1 inhibitor therapy independently predicted progression-free survival. |
| Publish Date |
2026-11-05 02:51 |
| Citation |
Ma F, Zheng LY, Song DJ, Zhao ZW, Cao F, Hao WY, Qiu JQ, Lu D, Zheng JP. Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123385
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i11/123385.htm |
| DOI |
https://doi.org/10.4251/wjgo.123385 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
